Phase 3 N=1 Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
Iron Deficiency Anemia · Iron-deficiency
Primary: Percentage of Eligible Patients Enrolled — 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=390 Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia
Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants
Phase 3 N=149 Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 COVID-19
Primary: Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline — 56; 5; 27 Participants — p=.28
Phase 3 N=2,736 A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
COVID-19
Primary: Percentage of Participants Who Developed Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline…
Phase 3 N=2,654 Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
Influenza, Human
Primary: HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) — 1.9; 1.7; 2.7; 2.3 Geometric Mean Fold Ratio
Phase 3 N=1,307 P3 Study in Acne Comparing Once Daily SB204 and Vehicle
Acne Vulgaris
Primary: Absolute Change From Baseline in Inflammatory Lesion Counts — -12.4; -11.3 inflammatory acne lesions
Phase 3 N=66 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
Binge-Eating Disorder · Obesity
Primary: Binge Eating Frequency (Continuous) — 0.86; 3.25 binge eating days per month — p=.07
Phase 3 N=81 Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
Alcohol Dependence
Primary: Average Standard Drinking Units Per Day — 4.50; 4.48 standard drinking units per day — p=.98
Phase 3 N=153 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Hypercholesterolaemia
Primary: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand — 9.7; -33.6; -4.4; -38.2 percent…
Phase 3 N=93 The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19
Phase 3 N=706 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Alopecia Areata
Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24 — 0.8; 29.6; 41.5 percentage of participants — p=<0.0001
Phase 3 N=41 Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Primary Hyperparathyroidism
Primary: Change in Parathyroid Hormone Levels — 4.0; -3.7; 0.8 pg/mL — p=0.84
Phase 3 N=1,184 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
Pneumococcal Infections
Primary: Percentage of Participants That Report at Least 1 Solicited Injection-site Adverse Event (AE) — 45.3; 44.7; 41.9; 39.1 Percentage of Participants — p== 0.824
Phase 3 N=513 Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
Negative Symptoms of Schizophrenia
Primary: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) — 25.2; 25.3; 24.3; -1.2 score on a scale — p=0.043
Phase 3 N=26 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura
Primary: Number of Participants With Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm — 3; 1 participants